Pharma, whistleblower lessons learned from $900M Biogen settlement - Compliance Week
The high price on Biogen’s $900 million settlement for False Claims Act (FCA) violations shows the government is still keenly interested in cases of illegal kickbacks in physician referrals, exper...
Read more